(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 May 2020 (28.05.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/106898 A1

(51) International Patent Classification:
*A61K 31/337* (2006.01) *C07D 213/82* (2006.01)
*A61K 31/444* (2006.01)

(21) International Application Number:
PCT/US2019/062494

(22) International Filing Date:
20 November 2019 (20.11.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/770,437 21 November 2018 (21.11.2018) US

(71) Applicant: **LSK BIOPARTNERS, INC. D.B.A. ELEVAR THERAPEUTICS** [US/US]; 2825 E. Cottonwood Pkwy, Suite 180, Salt Lake City, Utah 84121 (US).

(72) Inventors: **MCGINN, Arlo N.**; 2825 E. Cottonwood Pkwy, Suite 180, Salt Lake City, Utah 84121 (US). **KIM, Bumjin**; 2825 E. Cottonwood Pkwy, Suite 180, Salt Lake City, Utah 84121 (US). **KIM, Sung Chul**; 2825 E. Cottonwood Pkwy, Suite 180, Salt Lake City, Utah 84121 (US). **PARK, Cheol Hee**; 2825 E. Cottonwood Pkwy, Suite 180, Salt Lake City, Utah 84121 (US).

(74) Agent: **KANG, Peter S.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PHARMACEUTICAL METHODS





FIG. 1

(57) Abstract: Provided herein are methods for the treatment of diseases, comprising administering a combination of a tyrosine kinase inhibitors and tubulin binding agent.

*[Continued on next page]*

WO 2020/106898 A1

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

— *with international search report (Art. 21(3))*